ABCL
NASDAQ HealthcareAbCellera Biologics Inc. - Common Shares
Biotechnology
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
๐ Market Data
| Price | $6.16 |
|---|---|
| Volume | 7,394,725 |
| Market Cap | 1.88B |
| Beta | 1.150 |
| RSI (14-Day) | 45.2 |
| 200-Day MA | $4.48 |
| 50-Day MA | $5.86 |
| 52-Week High | $8.44 |
| 52-Week Low | $2.75 |
| Forward P/E | -8.74 |
| Price / Book | 2.00 |
๐ฏ Investment Strategy Scores
ABCL scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ Moon Shot (72/100) โ this strategy High growth potential (high beta + oversold).
Lowest fit among scored strategies: ๐ฐ Dividend Daddy (23/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find ABCL in your text
Paste any article, transcript, or post โ the tool will extract ABCL and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-07-16.